Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Forkhead box D3 antisense RNA 1 (FOXD3-AS1) is a long non-coding RNA transcribed antisense to the FOXD3 gene, located at chromosome 1p31.3. FOXD3-AS1 acts as a competitive endogenous RNA and regulates expression of key genes involved in cell proliferation, apoptosis inhibition, migration, and chemoresistance, frequently by sponging tumor-suppressive microRNAs and modulating epigenetic marks such as H3K27 acetylation at gene promoters. Aberrant upregulation of FOXD3-AS1 is associated with malignancy and poor prognosis in a variety of cancers—including lung, nasopharyngeal, breast, colon, and thyroid carcinomas—and serves as a promising biomarker for cancer diagnosis and prognosis. Experimental FOXD3-AS1 knockdown represses cancer cell growth, invasion, and resistance to chemotherapy, although no approved drugs currently target FOXD3-AS1 directly[1][2][3][4][5].
Experimental inhibition of FOXD3-AS1 (e.g., via siRNA, shRNA, or antisense oligonucleotides) suppresses proliferation, migration, invasion, and chemoresistance in cancer models. It also epigenetically modulates gene expression by recruiting H3K27ac to promoters.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Forkhead box D3 antisense RNA 1 (FOXD3-AS1).